



# Updates from the Chair

June 20, 2024

Joe Zeleznik

Chair, IPEC-Americas

Multiple stakeholders; **one objective.**



# Volunteer Appreciation

THANK YOU  
TO OUR MANY  
VOLUNTEERS!

SPOTLIGHT  
ON.....

# 2<sup>nd</sup> Quarter Volunteer Spotlight



Kayla Thompson Allen

LIFE SCIENCES REGULATORY  
PROFESSIONAL - AMERICAS

.



# Federation Update

# IPEC Federation (Priscilla)

## ► IPEC Federation

- Comments were provided on:
  - ICH Q1 Stability draft (constituency review); IPEC comments were successfully incorporated at the ICH June meeting
  - WHO GMPs for Excipients used in Pharmaceutical Products
  - WHO GMPs for Excipients used in Pharmaceutical Products – Appendix 1 Risk Management in the Production & Control of Excipients
  - WHO GMPs for Excipients used in Pharmaceutical Products – Appendix 2 Examples of High Risk Excipients
    - Concerns raised within the Federation about WHO's perspectives on excipients
  - Participated in meeting with EFPIA & IFPMA re: WHO nitrosamines guideline and signed on to joint comment letter
  - ChP General Chapter 251 General Requirements for Excipients

## ► IPEC Federation

- Developing a model/process for expansion to other countries
  - One member company has proposed forming an IPEC organization in Korea
- Webinar on nitrosamines has been updated for the latest version of the position paper
- Plans to develop excipient education for regulators – build on IPEC-Americas Excipients 101 course
- Atypical Actives – proposal to elevate to Fed. Level project

## • **IPEC EU**

- Still waiting for EMA Q&A on co-processed excipients - focused on quality, not inspections
- EMA inspectors WG reported inspection deficiencies of pharma companies with their formal risk assessments for excipients; this may contribute to the CPE issue; consider this in revision of PDA/IPEC Risk Assessment guide
- Monitoring proposed EU Pharma Regulations
- Published summary of March Lhasa workshop on nitrosamines

## • **IPEC India**

- Annual conference held May 31; IPEC Federation speaker for EG/DEG

- **IPEC Japan**

- Holding conference in July for those new to excipients

- **IPEC China**

- Conference in October; no longer affiliated with CCFDIE
- New website
- PEG monographs under revision – aligning EG/DEG limits with other pharmacopeia
- Submitting comments for ChP Gen. Chapter 251
- Will hold excipient GMP training session in Oct. in collaboration with EXCiPACT®



# Committee Updates

# Compendial Review and Harmonization Committee



Chair: Douglas Muse  
Sr. Principal Associate,  
Compendial Affairs  
Eli Lilly and Company

Vice Chair:  
Volunteer Needed

# Compendial Review (CRC)

- **Monthly Compendial Review Meetings** overview –
  - PF 50(3) and PharmEuropa 36.2 and new effective content USP/NF 2024 Issue 3.
  - Comments submitted to proposed revisions to USP General Notices published in PF 50(2)
- **Provided training** on use of new IPEC-Americas website capability for monitoring CRC postings and communication
- **Provided updates** for IPEC-Americas activities with SEPC – Stakeholder Engagement Planning Committee, CPPQ – Compendial Policy, Process, and Quality stakeholder organization, JIG – Joint Industry Group Meeting and a QC Laboratory Instrument survey.
- **Reviewed Federation project activities** for Mutual recognition project and PDG Polysorbate 20 harmonization project team.
- **Discussed ChP GC <0251> Pharmaceutical Excipients.** Comments due by June 30 to Federation. Highlights will be reviewed/captured during User Network meeting
- **Deep dive discussion into the USP Convention 2025-2030 documents.** Reviewed and developed comments and/or endorsements for:
  - draft proposed USP convention bylaw amendments.
  - USP proposed resolution concepts

# Regulatory Affairs Committee



Chair: Bob Sulouff  
Regulatory Affairs  
Advocacy Manager  
IFF



Vice Chair: Troy Barrix  
Principal Regulatory  
Compliance Specialist  
Celanese

# Regulatory Affairs

- **Reviewed US Regulatory Projects**

- Discussed developing a guide or white paper on strategy and issues with Novel Excipients that are not NCEs
- Provided update on Q2 IID postings and discussed inviting Amanda Jones (FDA OGD IID owner) to future meeting
- Provided update on Atypical Actives sub-team activities, including plans for escalation to Federation project.
- Reviewed Section 2.1.2 (Excipients) of a CVM draft guidance developed by the VICH working group entitled: [Pharmaceutical Development VICH GL61](#).

- **Regional Updates**

- Provided update on final microplastics regulation an efforts by Cefic and EFfCI to develop and publish their own “how to” guidance documents.
- Discussed ECHA SEAC (Socio-Economic Analysis) and RAC (committee for risk assessment) committees review and discussion on PFAS regulations as well as PFAS restrictions underway in Minnesota, Illinois and Kentucky

- **Other topics**

- Shared State Regulatory Tracking document – developed a spreadsheet (similar to TDMA TiO<sub>2</sub>) for listing substances that states are proposing to ban. Spreadsheet to identify states, ingredients, and status of any proposal (e.g. PFAS, TiO<sub>2</sub>).

# Good Manufacturing Practices Committee



Chair: Mike Cassell

cGMP Quality Assurance  
Manager

Eastman Chemical Company



Vice Chair: Beth Febbo

Global Laboratory & Project  
Manager

Henkel Corporation

# Good Manufacturing Practices

- **Submitted NSF/IPEC/ANSI Excipient GMP Standard to FDA for recognition as a consensus standard.**
- **Reviewed status of and progress towards IPEC Guides currently in-progress**
  - IPEC GDP How to Guide targeted for publication in September
  - IPEC Stability Guide and ICH Q1 Drug Substance and Product Stability guidance
- **Discussed potential guide revisions/ new position papers**
  - Comparison of excipient GMPs for IPEC vs ANSI vs USP vs EXCiPACT vs WHO
  - Update of IPEC-PQG Excipient GMP guide to include how to conduct risk assessments for parenteral, pediatric and inhalation products as well as requirements for contract manufacturers
- **Update on development of a new IPEC-Americas training/course**
  - Excipient GMP training including an introductory webinar targeted for October 2024.
- **Review of revised USP GC <1078> Excipient GMPs**
  - Review revision targeted for publication in December 2024 vs current version.

# Excipient Qualification Committee



Chair: Candy Reynolds-Cummings  
Quality Assurance and  
Regulatory Manager  
Evonik



Vice Chair: Kayla Thompson  
Allen  
Regulatory Professional, Food,  
Nutrition & Pharmaceuticals  
Ashland



# Excipient Qualification

- **Status updates provided for current project tracking activities.**
  - Volunteers have been identified (by Federation) and lined copies of the following Risk Assessment Guides were sent out (by Federation) for review and comment by June 19.
    - IPEC Risk Assessment Guide 2017
    - Joint PDA/IPEC TR No. 54-6 Formalized Risk Assessment for Excipients, 2019
  - Proposed corrections to 2022 IPEC CoA Guide were discussed and agreed to follow-up with both IPEC Federation and EXCiPACT®.
- **Sub team to discuss issues for introducing new excipients**
  - Initial sub-team meeting held in April. Minutes to be added to EQ Library.
- **IPEC-Americas sustainability focused discussion group**
  - Current group strongly soliciting and encouraging Users to participate in a cross functional team to discuss trends, needs and next steps. Interested parties should send a request to participate to [ipecamer@ipecamericas.org](mailto:ipecamer@ipecamericas.org)

# Quality by Design



Chair: David Schoneker  
Consultant  
Black Diamond Regulatory  
Consulting



Vice Chair: Stacey Bremer  
Director, Product  
Stewardship  
Celanese

# Quality by Design

- **Reviewed QbD webinars, articles and workshops**
  - PharmTech to publish an article on “Excipient considerations to ensure a robust CM process operation” on-line in June/July and in print in September
- **Hosted Sharon Nowak from K-Tron** (equipment manufacturer) to speak on Excipient Considerations for Continuous Manufacturing
- **Brainstormed ideas for future PQRI workshops.**
  - Re-initiated planning for a PQRI Workshop on Co-processed excipients that focuses on their use, functionality and performance, not regulatory aspects.
- **Discussed/proposed new/revised guides and projects**
  - Discussed project to better define excipient impurities and concomitant components and develop a strategy moving forward, including revisions to IPEC Glossary and guides
  - Reviewed and discussed Concomitant Component infographic.
  - Proposed new guide on Excipient Interchangeability based on recent article on [Supplier Qualification](#). Sub committee to review and update charter
  - Incorporating 2016 IPEC-Americas QbD Sampling Guide into 2020 IPEC Incorporation of Pharmaceutical Excipients into Product Development using Quality-by-Design (QbD) Guide.
  - Discussed re-engaging with FDA on additives and processing aids in pharmaceutical excipients

# Scientific Affairs Committee



Co-Chair: Alexa Smith

Director, Global Quality &  
Regulatory Services  
Colorcon



Co-Chair: Teresa Wegesser

Principal Scientist  
Amgen

# Scientific Affairs

- Discussed developing a guide or white paper on Novel Excipients that are not NCEs.
- Proposed a potential position paper, guide and/or guide supplement differentiating the concept between “Risk Assessment” and “Hazard Identification,” including the need for risk-based decisions to balance risk vs benefit.
- Suggested creating/communicating positive excipient messaging – how to develop a positive, simplistic message regarding the need for and benefits of excipients (benchmarking others, such as IFAC) and get the message out through social media.
- Shared recent draft WHO nitrosamine and ICH Q3E guidelines with IPEC-Americas members for comment.
- Shared USP Novel Excipient Hub and discussed how IPEC-Americas members might participate/contribute.
  - [USP Global Policy Position NovelExcipients Paper 2024.pdf](#)
  - LINK to Excipients Hub: <https://www.usp.org/excipients/novel-excipients>
- Promoted IPEC-Americas webinar entitled “Read-Across as an Alternative Approach for Assuring the Safety of Excipients” scheduled for October 30.
- Identified and briefly discussed a couple recent poorly reviewed scientific articles. Anyone identifying articles of concern should send copy to [ipecamer@ipecamericas.org](mailto:ipecamer@ipecamericas.org) with request to forward to SAC sub team members.

# Users Network



Chair: Jennifer Putnam  
Senior Supervisor AR&D  
Perrigo

# Users Network

- Brainstormed Atypical Actives including how users are managing their use as an API and what challenges other challenges they might have.
- Briefly discussed need to review ChP - <0251> Pharmaceutical excipients draft revision and provide any comment by June 30.
- Continued discussion (from Q1) for potential UN committee activities: Agreed to:
  - consider adding information on administration of biologics and parenterals as IPEC guides are updated.
  - Survey members to determine which guide updates would be most impactful to biologics and parenteral (could become a UN project)
- In addition, reminded committee of current documents out for comment



# Monthly Compendial Postings Review

- Reviewed new proposals published in PF 50(3) and PharmEuropa 36.2
- New/updated official content in USP/NF 2024 Issue 3 (effective 1-Dec-2024) reviewed during Q2 CRC
- Comments submitted to proposed changes to USP General Notices as published in PF 50(3)
- USP 2025-2030 Convention Cycle proposed resolution concepts and bylaw amendments under review for endorsement and/or comments
- Draft comment letters are now being posted to the CRC community library on the IPEC-Americas website to enable all members to provide input – set your communication preferences to receive notifications!!
- Next compendial postings review:
- 8-July-2024 1 – 2:30 pm EDT (Remote)



# IPEC-Americas 2024 Q2 Dashboard

5 interactions with regulators/ pharmacopoeias

|                              | CRC | RA | GMP | EQ | QbD | SAC | UN | LL | XC | IF | EW | M |   |
|------------------------------|-----|----|-----|----|-----|-----|----|----|----|----|----|---|---|
| FDA Docket comments          |     | 1  |     |    |     |     |    |    |    |    |    |   | 1 |
| FDA Correspondence           |     |    | 1   |    |     |     |    |    |    |    |    |   | 1 |
| FDA Public Mtg/training      |     |    |     |    |     |     |    |    |    |    |    |   | 0 |
| USP correspondence/meeting   | 2   |    |     |    |     |     |    |    |    |    |    |   | 2 |
| EDQM comments                |     |    |     |    |     |     |    |    |    |    |    |   | 0 |
| ECHA (REACH Comments)        |     |    |     |    |     |     |    |    |    |    |    |   | 0 |
| ICH Comments (ICH Q13 WG)    |     |    |     |    |     |     |    |    |    |    |    |   | 0 |
| OEHA                         |     |    |     |    |     | 1   |    |    |    |    |    |   | 1 |
|                              |     |    |     |    |     |     |    |    |    |    |    |   |   |
| Publications                 |     |    |     | 1  | 1   |     |    |    | 4  |    |    |   | 6 |
| Workshops                    |     | 1  | 1   | 1  | 1   |     |    |    |    |    | 2  |   | 6 |
| Webinars/Presentations       |     | 3  |     |    | 2   |     |    |    | 1  |    | 2  |   | 8 |
| Draft Guides (in-progress)   |     |    | 3   | 2  | 1   |     |    |    |    |    |    |   | 6 |
| Published New/Revised Guides |     |    |     | 2  |     |     |    |    |    |    |    |   | 2 |
| Position Papers/White Papers |     | 1  |     |    |     |     |    |    |    |    |    |   | 1 |
| Infographics                 |     |    |     |    |     |     |    |    | 1  |    |    |   | 1 |
| Position Papers/White Papers |     | 1  |     |    |     |     |    |    |    |    |    |   | 1 |
| Infographics                 |     |    |     |    |     |     |    |    | 1  |    |    |   | 1 |

M = membership

# IPEC Foundation

# IPEC Foundation Awards

The IPEC Foundation will still accept any additional awards applications. Submit before the end of June.

[www.ipecfoundation.org](http://www.ipecfoundation.org).



**The Foundation Awards Ceremony will take place in Salt Lake City, Utah, October 22, 2024.**

**Please submit candidates for the Industrial Research Award –**

**The Henk de Jong Industrial Research Award** recognizes individuals in industry for their outstanding achievements and contributions in excipient research and innovation.

# ICH Update

- Met in Fukuoka, Japan June 4-5, 2024
- **Membership** -ANMAT Argentina and JFDA Jordan have been approved as new members of ICH
- **New Topics** - New topic proposal on Nitrosamines - adopted
- **Implementation of ICH Guidelines: NMPA**
  - Q13 will be implemented 13 June 2024
  - Special thanks to Brian Carlin
- [ICH Official web site : ICH](#) – Press release
- Topic updates and presentations located on IPEC-Americas website



# Other Strategic Activities

# Latin America Working Group

## ➤ What's coming for 2024?

- A hybrid webinar initiative: November 19<sup>th</sup>, 2024
- Location: Merck Auditorium – Barueri – Sao Paulo - Brazil
  - Objective – Sharing knowledge about trending topics in the LATAM region, strengthening the presence and promoting the LATAM WG within excipients and pharmaceuticals stakeholders.
  - Hot topics for LATAM (nitrosamines, GMP, stability and atypical actives)
  - Audience: academia, industry, associations and local authorities.
- Ongoing meetings in local language
- If your company has business operations in Latin America who may want to participate in the working group please let IPEC-Americas Staff know.

# PQRI Activities

- IPEC-Americas plans to restart efforts for a workshop on Co-processed Excipients to Enhance Medicinal Product Development and Continuous Manufacturing. This workshop will primarily address the need for co-processed excipients and the performance benefits that they can bring to CM and drug development.
- PQRI's Product Quality Technical Committee (PQTC) is developing a project to address sustainability in the pharmaceutical industry including the pharmaceutical supply chain.
- PQRI Survey – post approval changes to Nasal Suspensions/Solutions <https://s.alchemer.com/s3/Regulatory-Challenges-for-Post-approval-Changes-of-Nasal-Spray-Products> (deadline extended to 7/31)
- <https://s.alchemer.com/s3/Regulatory-Challenges-for-Post-approval-Changes-of-Nasal-Spray-Products>

# PQRI Nominations

- Election of PQRI Steering Committee Vice Chair
- Congratulations to Dave Schoneker, representing IPEC-Americas!





# TiO<sub>2</sub> Update

- California has introduced a new bill to ban TiO<sub>2</sub> as well as all the synthetic FD&C colors for any foods sold in public schools. The bill has already passed the Assembly and is currently being debated in the Senate.
- Still waiting for FDA to publish their opinion on the Food additive petition submitted by the NGOs to ban TiO<sub>2</sub> in all foods in the U.S. FDA is expected to reject this petition based on their earlier outcomes and what they recently published on their website at: Titanium Dioxide as a Color Additive in Foods | FDA
- [Titanium Dioxide as a Color Additive in Foods | FDA](#)

# New Website Launch

- Higher Logic Platform
- Committee Communities
- Libraries – Public library, Member Library, Committee Library

# Website Adoption

- **Goals:**

- Short Term: Chairs as champions for member adoption
- Long Term: Website becomes effective communication/collaboration tool

- **Initiatives:**

- Awareness Efforts (Insider, Emails, Social Media)
- Training Resources (Live Webinars, Videos, Articles, etc.)
- Practice “Communities”

# Excipient Learning Lab



EXCIPIENT  
LEARNING  
LAB

| Date (2024)                             | Topic   | Presenter(s)  |
|---|---|---|
| January 17, 2024<br>11:00-1:00          | The Potential Impact of the EU TiO <sub>2</sub> Food Ban on Pharmaceuticals and Patients – Current Status | Dave Schoneker  |
| March 12 & 13<br>10:00-12:00            | Excipient Considerations in the Development and Approval of Animal Drug Products                          | GADA – CA, HS, SG<br>IA – Priscilla,<br>CVM – DL, KGR, AS, OS, SB |
| June 17 – 18, 2024                      | IPEC-Americas and Cobblestone Joint Course – Excipient: Compliance with Compendial and GMP Requirements   | Irwin Silverstein<br>Joe Abanese                                  |
| September 18-20, 2024                   | Excipient GMP Compliance in-Person Workshop   | Irwin Silverstein<br>Katherine Ulman                              |
| October ??, 2024                        | Excipient GMP 101 - basics of excipient GMPs  | Irwin Silverstein   |
| October 30, 2024 –<br>9:00am-11:am      | Read-Across as an Alternative Approach for Assuring the Safety of Excipients                              | George Daston (P&G), Jeff Pitt, Ron Filler, Teresa Wegesser       |
| November 6, 2024 -<br>12:00am to 2:00pm | Quality Management Maturity   | Jason Kerr (Moderna)  |
|   | POTENTIAL – Microplastics update – as new information becomes available                                   | Meera Raghuram  |
|   | POTENTIAL – Update for Regional excipient regulations (Europe, China, Latin America and the US)           | Priscilla Zawislak  |
|   | POTENTIAL – TiO <sub>2</sub> update – as new information becomes available                                | Dave Schoneker  |

# Excipient World Conference & Expo

## Successful event!

Gaylord Palms Resort & Convention Center Kissimmee, FL (Orlando metro area)

40 Booths

266 participants

39 speakers





# Location & Dates




**Conference:** May 12-14  
**Expo:** May 13-14

Gaylord National Resort  
& Convention Center  
(National Harbor, MD)




# Floorplan (as of 06.10.24)



22 booths  
already sold!

# ConComCom(ponents)

- **Purpose:**
  - Define where concomitant components get are in the manufacturing process.
  - What should users ask suppliers during the supplier/excipient qualification process to obtain the information they need?
- **Sponsor:** QbD Committee
- **Status:** One comment to go!





# NEW Infographic

- **Working Title:** Novel Excipients – Snapshot of Regulatory Process
- **Sponsor:** SAC
- **Goal:** Q3/Q4
- **Next Steps:**
  - Call for Volunteers
  - Draft Request Form



# International Journal of Pharmaceutical Excipients

- Formerly known as Journal of Excipients and Food Chemicals
- Keith Horspool, Ph.D., Chief Editor
- Undergoing rebrand
- Vol. 15, Issue 1, 2024 Transitioning to the Future



Published quarterly – Q2 Issue soon to be published

# 2024 Committee Weeks

- **Dates for 2024 “IPEC Week”**
- Q 3 - September 24-26
- Q 4 - December 3-5



Tuesday: Scientific Affairs Committee  
2:00 – 5:00 pm



Wednesday: CRC and RA 8:00 am –  
5:00 pm



Thursday: EQ and GMP Extended time  
8:00 am – 12:00 pm (flexible start time)



QbD/EC 1:00 – 4:00 pm



Monday following “IPEC Week”: Users  
Network: 2:00 – 3:00 pm

# Questions





IPECAmericas.org  
Education.IPECAmericas.org  
ExcipientWorld.org

Multiple stakeholders; **one objective.**

